CFM
LYEL icon

Cornerstone Financial Management’s Lyell Immunopharma LYEL Stock Holding History

Cornerstone Financial Management’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$646 Hold
46
– – ﹤0.01% 1242
2026
Q1 		$923 Hold
46
– – ﹤0.01% 1007
2025
Q4 		$1.42K Buy
+46
New +$1.03K ﹤0.01% 807

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Cornerstone Financial Management's LYEL Position: Q2 2026 in Review

Cornerstone Financial Management held its Lyell Immunopharma (LYEL) position steady in Q2 2026 at 46 shares worth $646. The position accounts for ﹤0.01% of the portfolio, ranked #1242.

Cornerstone Financial Management first reported a position in LYEL in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.42K in Q4 2025. 87 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

  • Cornerstone Financial Management held 46 shares of Lyell Immunopharma worth $646 as of Q2 2026.
  • Cornerstone Financial Management left its Lyell Immunopharma share count unchanged in Q2 2026.
  • Lyell Immunopharma made up ﹤0.01% of Cornerstone Financial Management's portfolio in Q2 2026, its #1242 holding.
  • Cornerstone Financial Management first reported a position in Lyell Immunopharma in Q4 2025 and has held it in 3 quarters since.
  • Cornerstone Financial Management's Lyell Immunopharma position peaked at $1.42K in Q4 2025.
  • 87 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on Cornerstone Financial Management's 13F filing for Q2 2026, filed 12 Aug 2026.